Shikhar Agarwal1, Akhil Parashar1, Samir R Kapadia1, E Murat Tuzcu1, Dhruv Modi1, Randall C Starling1, Guilherme H Oliveira2. 1. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. 2. Advanced Heart Failure and Transplantation Center and Onco-Cardiology Center, Division of Cardiovascular Medicine, Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, Ohio. Electronic address: guilherme.oliveira@uhhospitals.org.
Abstract
OBJECTIVES: This study compared the prognosis of patients with proximal cardiac allograft vasculopathy (CAV) treated with percutaneous intervention (PCI) to the prognosis of those with severe CAV not amenable to PCI. BACKGROUND: CAV is a progressive form of arterial narrowing affecting patients with orthotopic heart transplants (OHTs). PCI has been used to treat patients with focal CAV, but its efficacy remains unclear. METHODS: Of 853 patients undergoing OHT and subsequent coronary angiographies at the Cleveland Clinic, all patients with at least moderate CAV (>30%) on any coronary angiogram following OHT were included. Of remaining patients with no/mild CAV, 200 patients were randomly chosen to represent the comparison group. All angiograms of the included patients were reviewed and graded according to the International Society of Heart and Lung Transplantation (ISHLT) nomenclature. RESULTS: Of the 393 included patients, 100 patients underwent definitive intervention for CAV. Of these 100 patients, 90 patients underwent PCI only, 6 patients underwent coronary artery bypass grafting, and 4 patients underwent repeat OHT. We observed a progressive increase in long-term mortality with worsening CAV. Patients with ISHLT grade 3 CAV had the highest long-term mortality compared with other groups. In addition, there was a significant reduction in the risk for mortality at 2-year follow-up (adjusted odds ratio: 0.26; 95% confidence interval [CI]: 0.08 to 0.82) and 5-year follow-up (adjusted odds ratio: 0.28; 95% CI: 0.09 to 0.93) after PCI compared with patients diagnosed with ISHLT grade 3 CAV, who were deemed unsuitable for PCI. Furthermore, statin use was associated with a significant survival benefit in patients with CAV (hazard ratio: 0.21; 95% CI: 0.07 to 0.61). CONCLUSIONS: Worsening severity of CAV was associated with progressively worse long-term survival among heart transplant recipients. Among patients with CAV, long-term survival in those with CAV amenable to PCI was greater than that in those with severe CAV not treatable with PCI.
OBJECTIVES: This study compared the prognosis of patients with proximal cardiac allograft vasculopathy (CAV) treated with percutaneous intervention (PCI) to the prognosis of those with severe CAV not amenable to PCI. BACKGROUND: CAV is a progressive form of arterial narrowing affecting patients with orthotopic heart transplants (OHTs). PCI has been used to treat patients with focal CAV, but its efficacy remains unclear. METHODS: Of 853 patients undergoing OHT and subsequent coronary angiographies at the Cleveland Clinic, all patients with at least moderate CAV (>30%) on any coronary angiogram following OHT were included. Of remaining patients with no/mild CAV, 200 patients were randomly chosen to represent the comparison group. All angiograms of the included patients were reviewed and graded according to the International Society of Heart and Lung Transplantation (ISHLT) nomenclature. RESULTS: Of the 393 included patients, 100 patients underwent definitive intervention for CAV. Of these 100 patients, 90 patients underwent PCI only, 6 patients underwent coronary artery bypass grafting, and 4 patients underwent repeat OHT. We observed a progressive increase in long-term mortality with worsening CAV. Patients with ISHLT grade 3 CAV had the highest long-term mortality compared with other groups. In addition, there was a significant reduction in the risk for mortality at 2-year follow-up (adjusted odds ratio: 0.26; 95% confidence interval [CI]: 0.08 to 0.82) and 5-year follow-up (adjusted odds ratio: 0.28; 95% CI: 0.09 to 0.93) after PCI compared with patients diagnosed with ISHLT grade 3 CAV, who were deemed unsuitable for PCI. Furthermore, statin use was associated with a significant survival benefit in patients with CAV (hazard ratio: 0.21; 95% CI: 0.07 to 0.61). CONCLUSIONS: Worsening severity of CAV was associated with progressively worse long-term survival among heart transplant recipients. Among patients with CAV, long-term survival in those with CAV amenable to PCI was greater than that in those with severe CAV not treatable with PCI.
Authors: Travis B DeSa; Muhannad A Abbasi; Julie A Blaisdell; Kai Lin; Jeremy D Collins; James C Carr; Michael Markl Journal: Clin Imaging Date: 2019-12-19 Impact factor: 1.605
Authors: Jung-Min Ahn; Frederik M Zimmermann; Satish Arora; Ole-Geir Solberg; Oskar Angerås; Katrine Rolid; Muzammil Rafique; Lars Aaberge; Kristjan Karason; Kozo Okada; Helen Luikart; Kiran K Khush; Yasuhiro Honda; Nico H J Pijls; Sang Eun Lee; Jae-Joong Kim; Seung-Jung Park; Lars Gullestad; William F Fearon Journal: Eur Heart J Date: 2021-12-21 Impact factor: 35.855
Authors: Jessica G Y Luc; Jae Hwan Choi; Syed-Saif Abbas Rizvi; Kevin Phan; Ester Moncho Escrivà; Sinal Patel; Gordon R Reeves; Andrew J Boyle; John W Entwistle; Rohinton J Morris; H Todd Massey; Vakhtang Tchantchaleishvili Journal: Ann Cardiothorac Surg Date: 2018-01
Authors: G Galli; K Caliskan; A H M M Balk; R van Domburg; O Birim; J Salerno-Uriarte; O C Manintveld; A A Constantinescu Journal: Neth Heart J Date: 2016-12 Impact factor: 2.380
Authors: Sonia Mirabet; Alvaro García-Osuna; Pablo Garcia de Frutos; Andreu Ferrero-Gregori; Vicens Brossa; Laura Lopez; Ruben Leta; Joan Garcia-Picart; Josep M Padro; José Luis Sánchez-Quesada; Juan Cinca; Jordi Ordonez-Llanos; Eulalia Roig Journal: Dis Markers Date: 2018-08-29 Impact factor: 3.434
Authors: Bartlomiej Guzik; Elżbieta Szczepanek; Łukasz Niewiara; Marcin Nosal; Karol Wierzbicki; Marcin Krzanowski; Piotr Szolc; Bogusław Kapelak; Krzysztof F Żmudka Journal: Arch Med Sci Date: 2020-04-18 Impact factor: 3.318